Harrow Health, Inc. (HROW) News
Filter HROW News Items
HROW News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
HROW News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest HROW News From Around the Web
Below are the latest news stories about HARROW INC that investors may wish to consider to help them evaluate HROW as an investment opportunity.
Harrow Appoints Amir H. Shojaei as Chief Scientific OfficerNASHVILLE, Tenn., January 07, 2025--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that Amir H. Shojaei, PharmD, PhD, has joined Harrow as Chief Scientific Officer (CSO). With a remarkable career spanning 28 years in life sciences, Dr. Shojaei brings deep expertise in clinical development, regulatory affairs, and the commercialization of biopharmaceutical and biologic products, including groundbreaking work in anterior and posterior segment ophtha |
3 US Growth Stocks With Insider Ownership Expecting Up To 85% Earnings GrowthAs the U.S. stock market inches higher in a holiday-shortened session, with indices like the Nasdaq Composite and S&P 500 posting modest gains, investors are keeping a close eye on growth stocks that demonstrate robust potential amid fluctuating economic conditions. In this context, companies with high insider ownership can be particularly appealing, as significant insider stakes often signal confidence in the company's future prospects and alignment of interests between management and... |
US Growth Stocks With High Insider Ownership To WatchAs the U.S. stock market continues to reach new heights, with the Dow Jones Industrial Average closing at a record high and major indices posting weekly gains, investors are increasingly focused on identifying promising opportunities in this thriving environment. In such a robust market, stocks of growth companies with high insider ownership can be particularly appealing due to their potential for alignment between management and shareholder interests, offering a compelling case for those... |
Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.NASHVILLE, Tenn., November 21, 2024--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced a favorable jury verdict in the case of ImprimisRx, LLC v. OSRX, Inc. ImprimisRx, a wholly owned subsidiary of Harrow, brought the lawsuit to a jury trial in a San Diego, California, federal court alleging willful acts of trademark infringement against OSRX, Inc. and its related party, Ocular Science, Inc. An eight-person jury in the United States District Court fo |
Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract SurgeryNASHVILLE, Tenn., November 20, 2024--Melt Pharmaceuticals, Inc. ("Melt"), a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced positive topline results of its pivotal Phase 3 study evaluating the safety and efficacy of its lead product candidate, MELT‑300, a non-IV, non-opioid tablet for procedural sedation during cataract surgery. Based on a Special Protocol Assessment agreement reached with the U.S. Food and Drug Administration ("FDA") ea |
Harrow Announces Participation in Upcoming Investor ConferencesNASHVILLE, Tenn., November 15, 2024--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following three investor conferences: |
Harrow Inc (HROW) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Growth Amid ...Harrow Inc (HROW) reports a 44% revenue increase, strategic pivots, and addresses inventory challenges in its Q3 2024 earnings call. |
Harrow Announces Third Quarter 2024 Financial ResultsNASHVILLE, Tenn., November 13, 2024--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the third quarter and nine months ended September 30, 2024. The Company also posted its third quarter Letter to Stockholders and corporate presentation to the "Investors" section of its website, harrow.com. The Company encourages all Harrow stockholders to review these documents, which provide additional details concerning the historical quarterly period and |
Harrow Launches Access and Affordability Program with Price Reductions for Branded ProductsNASHVILLE, Tenn., November 13, 2024--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced an innovative initiative to expand access and affordability for its ophthalmic pharmaceutical products. This effort includes a program of targeted price reductions for several Harrow products and a strategic partnership with GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., providing patients with discounts on select Harrow products. Thi |
Harrow Announces Market Access Wins for VEVYE®NASHVILLE, Tenn., November 12, 2024--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced its first major market access wins in the 2025 Medicare Part D Prescription Drug Program. Starting January 1, 2025, VEVYE will be included in key formularies managed by major plan sponsors such as Express Scripts, Cigna, Kaiser Permanente, and CVS Caremark. In the aggregate, these sponsors represent over 25 million Medicare Part D beneficiaries. |